Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed missed EPS expectations, indicating financial instability. Despite promising partnerships and clinical milestones, setbacks in gene therapy and reliance on partnerships pose risks. Regulatory challenges and market competition further add to uncertainties. The Q&A highlighted management's evasive responses and potential risks in clinical trials. Overall, the negative sentiment from financial results and uncertainties outweighs the positives, suggesting a negative stock price reaction.
Key Financial Performance
Reported EPS $-0.59 EPS, down from $-0.35 year-over-year.
Cash $332 million in cash as of the end of 2024, with $8.2 billion in potential future milestone payments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VY1706 Development Progress: VY1706, a tau silencing gene therapy, has advanced into IND-enabling studies and is expected to reach IND status in 2026.
VY7523 Anti-Tau Antibody Study: VY7523 performed well in a single ascending dose study with no serious adverse events and initiated a multiple ascending dose study in Alzheimer’s patients.
Partnerships and Revenue: Voyager has $332 million in cash and $8.2 billion in potential future milestone payments from partnerships, indicating strong market positioning.
SOD1 Gene Therapy Program: The SOD1 silencing gene therapy program has moved back into the research stage due to the payload not meeting target profiles.
Focus on Gene Therapy: Voyager emphasizes the importance of IV delivery and genetically validated targets in severe diseases, differentiating its approach from broader gene therapy trends.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Earnings Expectations: Voyager Therapeutics missed earnings expectations with a reported EPS of $-0.59, compared to expectations of $-0.35, indicating potential financial instability.
Gene Therapy Setbacks: The SOD1 silencing gene therapy program was moved back into the research stage due to the payload not meeting target profiles, highlighting challenges in product development.
Regulatory Challenges: The advancement of VY1706 into IND-enabling studies is contingent on regulatory approval, which poses a risk to timelines and project viability.
Market Competition: The company faces competitive pressures in the gene therapy market, particularly with established products like Zolgensma, which may impact market share and investor confidence.
Partnership Reliance: While partnerships provide significant non-dilutive revenue, reliance on these partnerships for future milestones ($8.2 billion potential) poses a risk if new partnerships are not secured.
Clinical Trial Risks: The ongoing clinical trials, including the multiple ascending dose study for VY7523, carry inherent risks of adverse events and regulatory scrutiny that could affect future development.
Economic Factors: General economic conditions may impact funding and investment in biotech, which could affect Voyager's operational capabilities and growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Pipeline Development: Voyager has four wholly owned and 13 partnered programs, with a focus on two wholly owned programs targeting tau in Alzheimer's disease.
Partnerships: Voyager has generated significant non-dilutive revenue through partnerships, reporting $332 million in cash and $8.2 billion in potential future milestone payments.
Gene Therapy Approach: Voyager emphasizes the importance of IV delivery and genetically validated targets in severe diseases, differentiating its approach from the broader gene therapy field.
VY1706 Progress: VY1706, a tau silencing gene therapy, has advanced into IND-enabling studies and is expected to reach IND by 2026.
VY7523 Development: VY7523, an anti-tau antibody, has shown promising results in a single ascending dose study and is moving into a multiple ascending dose study in Alzheimer’s patients.
Future Milestones: Voyager anticipates sharing more data on its tau programs at upcoming conferences, including ADPD in April and AAIC in July.
Financial Outlook: The company expects partnerships to continue contributing significantly to its bottom line, with a focus on generating clinical data in the coming years.
Revenue Expectations: Voyager's partnerships are projected to yield $8.2 billion in potential future milestone payments.
Clinical Data: Initial tau PET data from the VY7523 study is expected in the second half of 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide additional color ahead of ADPD regarding external readouts in the tau space?
A:At ADPD, I hope to see data from bepranemab on exposure PD relationship and more data on tau spreading decrease needed for clinically relevant effects. Also, information on subgroups with greater efficacy, like APOE4 carrier status.
Q:What are your thoughts on upcoming milestones from Neurocrine or additional external partnerships?
A:There’s $2.9 billion of developmental milestones, which are not included in our guidance, representing additional upside to our mid-2027 cash runway guidance.
Q:Can you provide details on what needs to be completed before the tau gene silencing IND can be filed next year?
A:We need to complete the GLP tox study and ensure we have a therapeutic window without safety issues.
Q:What indications are you considering for the ALPL shuttle?
A:We’re looking broadly across various diseases and targets, including spinal cord and cerebral cortex diseases, and assessing the transport of proteins, antibodies, and oligonucleotides.
Q:What are the key differences expected between tau silencing and targeting antibodies?
A:The knockdown approach allows for better bio-distribution and broader tau knockdown, while antibodies target populations where tau has not yet spread.
Q:What are the key differences between the two tau approaches in preclinical studies?
A:Both approaches show positive results, but the knockdown approach may reduce the amount of tau and impede its spread.
Q:What is the MAD study design and how has it been informed by bepranemab results?
A:The MAD study focuses on earlier MCI and AD populations with lower tau, adjusting based on bepranemab data.
Q:What are the limitations of TfR-based brain shuttles?
A:TfR-based shuttles may lead to hematologic adverse events due to their critical role in iron transport, while ALPL may be more tolerable.
Q:What are the key results needed to make a decision on the anti-tau antibody program?
A:I’m looking for a clinically significant effect on tau spreading, similar to the 30% effect seen with anti-amyloid antibodies on CDR sum of boxes.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding specific data comparisons between their antibody and Merck's antibody, as well as the exact timing and details of the MAD study.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Affairs Officer
Chief Corporate
Chief Medical
Corporate Affairs
End Financial
Financial Results
Inc expectation
Investors section
Medical Officer
Officer Dr
Officer Voyager
Officer milestone
QA Dr
Slide today
Therapeutics End
Therapeutics Inc
Transcript Voyager
Voyager Therapeutics
Voyager afternoon
Voyager representative
afternoon Voyager
afternoon end
answer session
belief risk
completion Chief
detail Al
end result
end today
expectation afternoon
expectation belief
factor SEC
hour
milestone QA
statement Slide
VYGR Transcript
Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Neutral3-3
Voyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference Transcript
Neutral9-2
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call Transcript
Unknown3-12
The earnings call revealed missed EPS expectations, indicating financial instability. Despite promising partnerships and clinical milestones, setbacks in gene therapy and reliance on partnerships pose risks. Regulatory challenges and market competition further add to uncertainties. The Q&A highlighted management's evasive responses and potential risks in clinical trials. Overall, the negative sentiment from financial results and uncertainties outweighs the positives, suggesting a negative stock price reaction.
Voyager Therapeutics, Inc. (VYGR) Q4 2024 Earnings Call Transcript
Positive3-11
The earnings call highlights strong financial health with $332 million cash and $8.2 billion in potential milestone payments. Key partnerships and promising gene therapy developments indicate positive business momentum. The Q&A section reveals optimism about upcoming milestones and external partnerships, despite some management ambiguity. Overall, the financial outlook and strategic advancements suggest a positive stock price movement.
VYGR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
